Search Orphan Drug Designations and Approvals
-
| Generic Name: | An autologous chimeric antigen receptor (CAR) T-cell therapy engineered to express an antibody-derived single-chain variable fragment that recognizes C-type lectin-like molecule-1 (CLL-1). |
|---|---|
| Date Designated: | 09/27/2022 |
| Orphan Designation: | Treatment of acute myeloid leukemia (AML) |
| Orphan Designation Status: | Designated/Designation Withdrawn or Revoked |
| FDA Orphan Approval Status: | Not FDA Approved for Orphan Indication |
| Sponsor: |
Kite Pharma, Inc. 2400 Broadway Santa Monica, California 90404 United States The sponsor address listed is the last reported by the sponsor to OOPD. |
*Data for the Date Designation Withdrawn or Revoked field are shown for designations withdrawn or revoked after 08/12/2013.
-







